NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Target Raised at Cantor Fitzgerald

NewAmsterdam Pharma (NASDAQ:NAMS) had its price target upped by Cantor Fitzgerald from $52.00 to $61.00 in a report issued on Wednesday, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other research analysts also recently issued reports about the company. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Royal Bank Of Canada cut their price target on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, October 5th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, October 15th. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma has an average rating of “Moderate Buy” and an average price target of $49.82.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $20.72 on Wednesday. NewAmsterdam Pharma has a 1 year low of $17.90 and a 1 year high of $42.21. The company has a market capitalization of $2.48 billion, a P/E ratio of -12.26 and a beta of 0.15. The company’s fifty day moving average is $21.75 and its two-hundred day moving average is $29.31.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.33. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $8.82 million. NewAmsterdam Pharma had a negative return on equity of 31.39% and a negative net margin of 789.95%. As a group, equities analysts expect that NewAmsterdam Pharma will post -1.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director John W. Smither sold 1,600 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the transaction, the director owned 8,760 shares in the company, valued at $221,803.20. This trade represents a 15.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael H. Davidson purchased 10,000 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were purchased at an average cost of $22.65 per share, with a total value of $226,500.00. Following the purchase, the chief executive officer directly owned 792,923 shares in the company, valued at approximately $17,959,705.95. The trade was a 1.28% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have sold 176,846 shares of company stock worth $4,661,919. 12.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently made changes to their positions in NAMS. Summit Wealth Group LLC acquired a new position in NewAmsterdam Pharma during the third quarter worth about $730,000. Knights of Columbus Asset Advisors LLC lifted its holdings in shares of NewAmsterdam Pharma by 28.0% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 56,070 shares of the company’s stock valued at $1,364,000 after purchasing an additional 12,270 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in shares of NewAmsterdam Pharma by 1.3% in the third quarter. Kornitzer Capital Management Inc. KS now owns 141,711 shares of the company’s stock valued at $3,446,000 after purchasing an additional 1,778 shares in the last quarter. AlphaCentric Advisors LLC grew its position in shares of NewAmsterdam Pharma by 4.6% in the third quarter. AlphaCentric Advisors LLC now owns 15,549 shares of the company’s stock valued at $378,000 after purchasing an additional 681 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in shares of NewAmsterdam Pharma by 43.7% in the third quarter. Parallel Advisors LLC now owns 2,012 shares of the company’s stock valued at $49,000 after purchasing an additional 612 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Latest NewAmsterdam Pharma News

Here’s some of the latest news about NAMS:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $61 from $52 and reiterated an “Overweight” rating. The new target implies substantial upside from the referenced $20.72 share price and may support investor sentiment. Tickerreport.com article
• Neutral Sentiment: A report claims short interest increased but then lists short interest as zero shares and days to cover as zero. The contradictory figures make this difficult to interpret as a reliable trading signal.
• Negative Sentiment: HC Wainwright maintained its “Buy” rating and $52 target, but lowered several forecasts: Q4 2026 loss per share to $0.43 from $0.28, FY2027 to a loss of $1.48 from projected earnings of $2.15, FY2028 earnings to $1.30 from $3.66, and FY2029 earnings to $5.72 from $6.84. Those cuts temper the bullish target news, though its FY2026 loss estimate improved and its FY2030 earnings forecast edged higher.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.